Abstract

The present invention provides rebamipide for use in a method of prevention and/or treatment of celiac disease, particularly in a person suffering from increased intestinal permeability or in a person who is at risk of increased intestinal permeability. Furthermore, it provides rebamipide for use in a method of inhibiting a gluten-induced increase in intestinal permeability.

IPC Classes  ?

• A61K 31/4704 - 2-Quinolinones, e.g. carbostyril
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention relates to the use of rebamipide in a method of prevention and/or treatment of arterial stiffness and associated diseases, such as hypertension, heart failure, myocardial infarction, stroke, peripheral arterial disease, renal failure, and chronic kidney disease. Rebamipide may also be used in a method of increasing arterial elasticity.

IPC Classes  ?

• A61K 31/4704 - 2-Quinolinones, e.g. carbostyril
• A61P 9/00 - Drugs for disorders of the cardiovascular system

Abstract

The present invention relates to rebamipide for use in a method of prophylaxis and/or treatment of cancer in a person suffering from increased intestinal permeability or in a person who is at risk of increased intestinal permeability, e.g. due to family anamnesis or due to exposure to conditions or substances inducing increased intestinal permeability.

IPC Classes  ?

• A61K 31/4704 - 2-Quinolinones, e.g. carbostyril
• A61P 35/00 - Antineoplastic agents
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

The present invention provides rebamipide for use in a method of prevention and/or treatment of Crohn's disease. In particular, rebamipide is used in prevention and/or treatment of Crohn's disease in a person suffering from increased intestinal permeability or in a person who is at risk of increased intestinal permeability.

IPC Classes  ?

• A61K 31/4704 - 2-Quinolinones, e.g. carbostyril
• A61P 1/12 - Antidiarrhoeals
• A61K 31/606 - Salicylic acidDerivatives thereof having amino groups
• A61K 31/655 - Azo (—N=N—), diazo (=N2), azoxy (N—O—N or N(=O)—N), azido (—N3) or diazoamino (—N=N—N) compounds
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 38/13 - Cyclosporins
• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• A61K 31/4164 - 1,3-Diazoles
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum

Abstract

The present invention provides rebamipide for use in a method of prevention and/or treatment of a synucleinopathy, in particular of Parkinson's disease. In particular, rebamipide is used in prevention and/or treatment of a synucleinopathy in a person suffering from increased intestinal permeability or in a person who is at risk of increased intestinal permeability.

IPC Classes  ?

• A61K 31/4704 - 2-Quinolinones, e.g. carbostyril

Abstract

The present invention relates to the use of rebamipide in a method of prevention and/or treatment of arterial stiffness and associated diseases, such as hypertension, heart failure, myocardial infarction, stroke, peripheral arterial disease, renal failure, and chronic kidney disease. Rebamipide may also be used in a method of increasing arterial elasticity.

IPC Classes  ?

• A61K 31/4704 - 2-Quinolinones, e.g. carbostyril
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 9/12 - Antihypertensives
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

Abstract

The present invention relates to the use of rebamipide in a method of prevention and/or treatment of arterial stiffness and associated diseases, such as hypertension, heart failure, myocardial infarction, stroke, peripheral arterial disease, renal failure, and chronic kidney disease. Rebamipide may also be used in a method of increasing arterial elasticity.

IPC Classes  ?

• A61K 31/4704 - 2-Quinolinones, e.g. carbostyril
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 9/12 - Antihypertensives
• A61P 9/14 - VasoprotectivesAntihaemorrhoidalsDrugs for varicose therapyCapillary stabilisers

Abstract

The present invention relates to rebamipide for use in a method of prophylaxis and/or treatment of cancer in a person suffering from increased intestinal permeability or in a person who is at risk of increased intestinal permeability, e.g. due to family anamnesis or due to exposure to conditions or substances inducing increased intestinal permeability.

IPC Classes  ?

• A61K 31/4704 - 2-Quinolinones, e.g. carbostyril
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention provides rebamipide for use in a method of prevention and/or treatment of Crohn's disease. In particular, rebamipide is used in prevention and/or treatment of Crohn's disease in a person suffering from increased intestinal permeability or in a person who is at risk of increased intestinal permeability.

IPC Classes  ?

• A61K 31/4704 - 2-Quinolinones, e.g. carbostyril
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system

Abstract

: The present invention provides rebamipide for use in a method of prevention and/or treatment of celiac disease, particularly in a person suffering from increased intestinal permeability or in a person who is at risk of increased intestinal permeability. Furthermore, it provides rebamipide for use in a method of inhibiting a gluten-induced increase in intestinal permeability.

IPC Classes  ?

• A61K 31/4704 - 2-Quinolinones, e.g. carbostyril
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system

Abstract

: The present invention provides rebamipide for use in a method of prevention and/or treatment of celiac disease, particularly in a person suffering from increased intestinal permeability or in a person who is at risk of increased intestinal permeability. Furthermore, it provides rebamipide for use in a method of inhibiting a gluten-induced increase in intestinal permeability.

IPC Classes  ?

• A61K 31/4704 - 2-Quinolinones, e.g. carbostyril
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Abstract

The present invention relates to rebamipide for use in a method of prophylaxis and/or treatment of cancer in a person suffering from increased intestinal permeability or in a person who is at risk of increased intestinal permeability, e.g. due to family anamnesis or due to exposure to conditions or substances inducing increased intestinal permeability.

IPC Classes  ?

• A61K 31/4704 - 2-Quinolinones, e.g. carbostyril
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention provides rebamipide for use in a method of prevention and/or treatment of Crohn's disease. In particular, rebamipide is used in prevention and/or treatment of Crohn's disease in a person suffering from increased intestinal permeability or in a person who is at risk of increased intestinal permeability.

IPC Classes  ?

• A61K 31/4704 - 2-Quinolinones, e.g. carbostyril
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone

Abstract

The present invention provides rebamipide for use in a method of prevention and/or treatment of a synucleinopathy, in particular of Parkinson´s disease. In particular, rebamipide is used in prevention and/or treatment of a synucleinopathy in a person suffering from increased intestinal permeability or in a person who is at risk of increased intestinal permeability.

IPC Classes  ?

• A61K 31/4704 - 2-Quinolinones, e.g. carbostyril
• A61P 25/16 - Anti-Parkinson drugs